GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) announced that GFH375, an oral KRAS G12D (ON/OFF) inhibitor, has been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA). The designation applies to KRAS G12D‑mutant non‑small cell lung cancer (NSCLC) patients who have received at least one prior systemic therapy, supported by best‑in‑class Phase 1/2 data demonstrating superior monotherapy efficacy and manageable safety.
KRAS G12D‑specific (vs. pan‑KRAS or G12C‑specific inhibitors)
Global Partnership – Verastem Collaboration
Parameter
Detail
Partnership Type
Discovery and development collaboration
Scope
Three novel oncology programs (RAS/MAPK pathway‑driven cancers)
Partner
Verastem, Inc.
Verastem Rights
Exclusive option to license each compound
Lead Program Selection
Dec 2023: Verastem selected GFH375/VS‑7375
Verastem Territory
Development and commercialization rights outside of China
GenFleet Retained Rights
Greater China (mainland, Hong Kong, Macau, Taiwan)
Strategic Implications
KRAS G12D “Undruggable” Target: KRAS G12D is the most common KRAS mutation in NSCLC (~ 4% of all cases) and historically resistant to direct targeting; GFH375’s ON/OFF mechanism and best‑in‑class efficacy validate a breakthrough approach.
Breakthrough Therapy Advantage: CDE BTD provides expedited review, enhanced CDE engagement, and potential priority review upon NDA submission—accelerating time‑to‑market for this high‑unmet‑need population.
Verastem Global Expansion: The ex‑China partnership with Verastem ensures parallel global development, leveraging Verastem’s US/EU regulatory expertise while GenFleet retains domestic commercial upside.
RAS/MAPK Platform: The three‑program collaboration with Verastem establishes GenFleet as a leader in RAS pathway drug discovery, with potential for additional KRAS variant inhibitors and combination therapies.
Market Context
Factor
Impact
KRAS G12D Prevalence
~ 4% of NSCLC; ~ 12‑15% of pancreatic cancer; ~ 5% of colorectal cancer—large addressable market across solid tumors
Competitive Landscape
Mirati (BMS), Revolution Medicines, and others advancing KRAS G12D programs; GFH375’s best‑in‑class claim supported by head‑to‑head Phase 1/2 data
Oral Administration Advantage
vs. injectable competitors; improves patient compliance and outpatient management
China‑First Development
BTD in China potentially precedes US/EU regulatory milestones, establishing GenFleet’s domestic leadership
Forward‑Looking Statements This brief contains forward‑looking statements regarding Phase II/III development timelines, global regulatory pathways, and commercial potential for GFH375. Actual results may differ due to risks including competitive KRAS G12D program advancements, combination therapy requirements, and Verastem execution outside China.-Fineline Info & Tech
By Fineline Cube